cyrilzakka/clinical-trials huggingface dataset:
Linked Color Imaging/Magnifying Blue Laser Imaging vs. White Light for Adenomas and Serrated Lesions in Proximal Colon

Linked color imaging (LCI) and magnifying blue laser imaging (BLI) are two new imaging systems used in endoscopy which are recently developed. BLI was developed to compensate for the limitations of NBI. BLI shows a bright image of the digestive mucosa, enabling the detailed visualization of both the microstructure and microvasculature. However, BLI still is not able to obtain sufficient brightness for distant lesions. The newly developed LCI system (FUJIFILM Co.) creates clear and bright endoscopic images by using short-wavelength narrow-band laser light combined with white laser light on the basis of BLI technology. LCI makes red areas appear redder and white areas appear whiter. Thus, it is easier to recognize a slight difference in color of the mucosa. This is a study to determine if using LCI of the colon, rather than the usual white light on the colon, will improve the detection of flat adenomas and serrated polyps. The polyps are called serrated because of their appearance under the microscope after they have been removed. They tend to be located up high in the colon, far away from the rectum. They have been definitely shown to be a type of precancerous polyp and it is possible that using LCI will make it easier to see them, as they can be quite difficult to see with standard white light. LCI/BLI enables endoscopists to accurately describe the pit pattern of adenomas. By comparing White Light Endoscopy and LCI/BLI, it will show if there is any comparable advantage to using one or the other for lesion detection and assessment.

This is a randomized controlled trial comparing the use of linked color imaging (LCI) and magnifying blue laser imaging (BLI) versus standard white light for the detection of serrated lesions in the proximal colon (the colon proximal to the splenic flexure). The proximal colon has large intestine and many folds which will lead missing flat lesions. Recent studies have indicated that colonoscopy is more effective in preventing cancer in the left side of the colon than the right side of the colon. The reasons for this difference may be partly biologic, in that a special group of polyps known as serrated polyps, particularly sessile serrated adenomas, are located primarily proximal to the splenic flexure. These lesions are endoscopically subtle in that they are often flat, have the same color as the surrounding mucosa, and are hard to differentiate from normal mucosa. LCI makes red areas appear redder and white areas appear whiter. Thus, it is easier to recognize a slight difference in color of the mucosa. This study will test whether LCI will increase the detection of serrated lesions in a randomized controlled trial.

Eligibility Criteria:
Inclusion Criteria:

--Consecutive adult patients undergoing an outpatient colonoscopy

Exclusion Criteria:

* unable to provide informed consent
* had undergone prior resection of the colon
* inflammatory bowel disease
* familial adenomatous polyposis, Peutz-Jeghers syndrome or other polyposis syndromes.
Early High-volume Continuous Veno-venous Hemofiltration for Patients With Severe Acute Pancreatitis

The purpose of this study is to determine the effect and safety of early high-volume continuous veno-venous hemofiltration for patients with severe acute pancreatitis.

The investigators anticipated that early high-volume continuous veno-venous hemofiltration (EHVCVVH) would result in a decrease of the composite of persistent organ failure or death by eliminating inflammatory mediators in blood. This study is designed to evaluate the impact of EHVCVVH on patients with severe acute pancreatitis.

Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of severe acute pancreatitis
* written informed consent
* Time from onset of abdominal pain to admission ≤ 72 hours
* SIRS score ≥ 2

Exclusion Criteria:

* confirmed infection
* pregnancy
* patients needing emergency operation for abdominal compartment syndrome
* chronic renal diseases needing blood purification
* previous exploratory laparotomy for acute abdomen and diagnosis of pancreatitis during laparotomy
* acute flare-up of chronic pancreatitis
* malignancy
A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)

This is a study of opevesostat in healthy adult male participants. The purpose of this study is to understand the absorption, distribution, metabolism, and elimination of opevesostat in humans, as well as its pharmacokinetics (PK), metabolic profile, and safety and tolerability.


Eligibility Criteria:
Inclusion Criteria:

* Is a healthy male according to the assessment of the investigator
* Has a body mass index of 18.0 to 32.0 kg/m2
* Has regular bowel movements (i.e., average stool production of ≥1 and ≤3 stools per day)

Exclusion Criteria:

* Has the presence or history of clinically significant allergy requiring treatment
* Has a history of adrenal insufficiency
* Has veins not suitable for multiple venipunctures/cannulation
* Has previously taken part in more than 3 radiolabeled drug studies in the last 12 months
* Has donated blood or plasma within the previous 3 months or lost greater than 400 mL of blood
Nebulized Albuterol for Congestive Heart Failure Exacerbation

This is a randomized trial of the use of Albuterol in the setting of acute decompensated Congestive Heart Failure with radiographic evidence of Cardiogenic Pulmonary Edema.

The objective is to carry out a randomized blinded placebo-controlled trial of inhaled Albuterol as an early therapy for patients with decompensated Congestive Heart Failure. Compared to placebo, inhaled Albuterol will improve oxygenation and decrease the need for non-invasive ventilation in patients with Cardiogenic Pulmonary Edema.

Eligibility Criteria:
Inclusion Criteria:

* age 18-65 with shortness of breath and history of CHF
* pulmonary edema on chest xr

Exclusion Criteria:

* pregnancy
* clinical or ekg changes to suggest acute coronary syndrome
* history of copd or asthma
* history of albuterol on medication list
Virtual Colonoscopy (VC) for Primary Colorectal Screening

This study involves a primary VC screening for colorectal polyps. The research hypothesis is that VC screening, including surveillance of sub-cm polyps, is a safe and effective approach.

The purpose of this study is to use virtual colonoscopy screening to learn more about what happens to small colon polyps (less than 10 mm) over time. From this, we can find out whether it's safer to remove all colon polyps right away or leave the small ones in place and remove only those that grow to 10 mm or more.

Eligibility Criteria:
Inclusion Criteria:

* Medium-sized colorectal polyps (6-9 mm)

Exclusion Criteria:

* No medium-sized colorectal polyps (6-9 mm)
Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

The purpose of this study is to assess how fast IBI362 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.


Eligibility Criteria:
Inclusion Criteria:

* All Participants:

  o The weight of male subjects is not less than 50 kg, and the body weight of female subjects is not less than 45 kg, and the body mass index (BMI) is within the range of 20\~30 kilograms per meter squared (kg/m²), inclusive, at screening
* Healthy Participants:

  -- Healthy males or females as determined by medical history, physical examination, and other screening procedures, with normal renal function, assessed by estimated glomerular filtration rate (eGFR) ≥90 milliliters per minute (mL/min) at screening
* Participants with Renal Impairment:

  * Males or females with stable mild to severe renal impairment, assessed by eGFR

Exclusion Criteria:

* All Participants:

  * Pregnant or lactating women, or men or women who are of childbearing potential and are not willing to use contraception within 6 months from the screening period to the administration of the study drug
  * Have known allergies to IBI362 or related compounds
  * Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
  * Have serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>1.5× the upper limit of normal (ULN) or total bilirubin (TBL) \>1× ULN
  * Severe gastrointestinal diseases (such as active ulcer, pyloric obstruction, inflammatory bowel disease, etc.) occurred within 6 months before screening, or received gastrointestinal surgery or long-term use of drugs that directly affect gastrointestinal motility due to chronic gastrointestinal diseases
  * Have a history of acute and chronic pancreatitis, or serum amylase and/or lipase ≥ 1.5× ULN at screening, or fasting Triglyceride ≥ 5.64 mmol/L (500 mg/dl)
* Participants with Renal Impairment:

  * obstructive urinary tract diseases (such as urinary stones, urinary tract obstruction caused by abdominal space-occupying lesions, etc.) or renal dysfunction caused by special types of renal parenchymal damage (such as polycystic kidney, medullary sponge kidney, Renal tumors, etc.) and/or patients with renal impairment who have diseases that are not related to renal disease but can cause renal impairment (eg, renal artery stenosis, acute drug injury, severe infection, hypovolemia, heart failure, etc.).
  * Have a history of kidney transplant
  * The treatment medication and/or the treatment medication of other comorbid diseases have been taken stably for less than 1 month at screening, or there are new medications within 1 month before screening (except temporary or intermittent use of drugs, such as Erythropoietin once a month, or diuretics as needed, etc.), or received any drug known to alter renal tubular creatinine secretion within 14 days or 5 half-lives before screening, such as cimetidine D, trimethoprim or cibenzoline, etc.
NGX-4010 for the Treatment of Postherpetic Neuralgia

The purpose of the study is determine if an investigational drug, NGX-4010 (high-concentration capsaicin dermal patches) is effective in treating pain associated with post-herpetic neuralgia (PHN).

Participants will be randomly assigned to receive initial treatment according to one of three doses (application durations), and will receive either NGX-4010 patch (high-concentration capsaicin) or matching control (low-concentration capsaicin).

Participants who complete the study evaluations for 12 weeks will have the option of receiving up to 3 additional open-label re-treatments over 1 year.

Eligibility Criteria:
Key Eligibility Criteria:

* Must be diagnosed with PHN and be at least 6 months after crusting of the skin vesicles, with moderate to severe pain.
* Must not have significant pain due to causes other than PHN (for example, arthritis).
* Painful areas should not be located on the face, above the hairline of the scalp, and/or in proximity to mucous membranes.
* Must have intact and unbroken skin at the treatment area.
* Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (1-year).
* Must not have any implanted medical device (spinal cord stimulator, intrathecal pump or peripheral nerve stimulator) for the treatment of pain.
* Must not use topical pain medications for PHN.
* Must be able to comply with study requirements such as completing a daily pain diary, attending study visits and refraining from extensive travel during study participation.
* No significant medical problems of the heart, kidneys, liver or lungs, or cancer.
* No history or current problem with substance abuse.
Reproductive Health Outcomes in Young Patients with Ovarian Cancer After Surgical Treatment: a Retrospective Study

Ovarian cancer (OC) is the second commonest gynecological cancer with an overall incidence of 1.4% , associated with high mortality rate , There are three major types of ovarian cancers: epithelial ovarian carcinomas, germ cell tumors, and stromal cell tumors .

Ovarian cancer directly affects fertility, as treatment consists of surgical removal of the reproductive system and/or exposure to gonadotoxic agents. However, patients in early stages who meet established criteria can be treated with fertility-sparing surgeries and reach equivalent oncological results to those of traditional treatments. Fertility preservation techniques such as cryopreservation of oocytes, embryos and ovarian tissue may also be offered in some situations.

Ovarian cancer (OC) has a high mortality rate and usually presents late in advanced stage, which poses challenges to management. Better understanding of the disease biology and application of radical surgery (RS) to achieve no visible residual tumor, alongside with chemotherapy, may lead to longer survival amongst these patients. Our purpose is to find out the fertility and survival rates of women with Overian Cancer in reproductive women who underwent surgical intervention. Radical Surgery for Overian cancer is one of the most challenging procedures in gynecologic oncology surgery.


Eligibility Criteria:
Inclusion Criteria:

1. Women in reproductive age 18-45 yrs
2. Localized ovarian cancer
3. Patients undergoing surgical intervention

Exclusion Criteria:

1- Patients who refuse to participate in the study. 2 - children and manupausl women 3 - Diffuse peritoneal ,enteric and mesenteric disease or very poor patient 's performance status 4 -Patients who were treated with chemotherapy only and not operated
EMOTE: a Smartphone Application for Binge Eating Based on DBT Skills

Binge eating, whether formally diagnosed or occurring at subthreshold levels, is associated with adverse health consequences and decreased quality of life.

Access to accessible, cost-effective interventions that effectively address binge eating episodes is critical for individuals with this condition, and smartphone applications have demonstrated promise in treating binge eating and related disorders.

This study aims to evaluate the efficacy of eMOTE, a novel smartphone application for binge eating based on Dialectical Behavior Therapy (DBT) skills. For this purpose, a randomized controlled trial will be conducted in which women who self-report binge eating episodes will be randomly assigned to the app intervention group or a waiting list group.

eMOTE is a self-help application for women struggling with binge eating episodes. The application was developed based on DBT skills and has four modules: psychoeducation, mindfulness skills, emotion regulation skills, and distress tolerance skills. Additionally, it includes two self-monitoring diaries that allow the input of data related to food, behaviors, feelings, and exercises. The application content will be delivered through text, audios, and videos.

For this study, adult individuals with binge eating episodes who are fluent in Portuguese and own a smartphone will be recruited. The recruitment will be conducted through social media, the University of Porto, and other relevant institutions.

Participants who enrol in eMOTE will be required to fill out online self-report instruments and provide their body mass index (BMI) at baseline (T0), two months (T1), and four months after randomization (T2). A researcher not involved in the study will conduct the randomization process.

Participants will be randomly allocated to two groups: the experimental and control groups. In the experimental group, the participants will have access to eMOTE for eight weeks, while in the control group, the participants will be on a waiting list for eight weeks, and after this period, the participants will have access to eMOTE. The investigators will analyze the changes in the frequency of objective and subjective binge eating episodes, eating disorder psychopathology, BMI, intuitive eating, depression, anxiety, stress, compensatory behaviors, mindfulness, and difficulties in emotion regulation.

Eligibility Criteria:
Inclusion Criteria:

* female;
* aged 18 years or older;
* self-report at least one binge eating episode over the past four weeks;
* owned a smartphone;
* fluent in Portuguese.

Exclusion Criteria:

* attending psychotherapy (face-to-face or digital) or another clinical trial;
* body mass index below 18.5;
* self-report an average of eight or more episodes of binge eating or inappropriate compensatory behaviours per week;
* being pregnant;
* self-report bipolar disorder, psychotic disorder, substance abuse, suicidal ideation or borderline personality disorder.
Safety and Efficacy of Emergent TAVI in Patients With Severe AS

This is a single-centre, prospective, observational cohort study focusing on of patients suffering severe aortic valve stenosis (AS) undergoing emergent transcatheter aortic valve implantation (TAVI). AS patients undergoing emergent TAVI always have complicated clinical situations. Therefore, the aims of the study are to collect the incidence and outcomes of emergent TAVI in patients with severe symptomatic AS, to assess the safety and effectiveness of emergency TAVI system for severe AS, and to describe a more practical evidence of emergency TAVI system in severe AS patients.


Eligibility Criteria:
Inclusion Criteria:

1. Every patient that diagnosed with severe aortic valve stenosis (evaluated by echocardiography: peak transaortic valve blood flow rate ≥4.0m/s, or mean transaortic valve pressure gradient ≥40mmHg (≥5.32kPa), or aortic Valve area \<0.8cm2, or AVA\<0.5cm2/m2);
2. Every patient that 1) required cardiopulmonary resuscitation due to cardiac arrest, or requiring external chest compressions during surgery (Salvage), 2) or has ongoing, refractory (difficult, complicated, and/or unmanageable) unrelenting cardiac compromise, with or without hemodynamic instability, and not responsive to any form of therapy except cardiac surgery (STS/ACC TVT defined "Urgent Status"), 3) or required urgent procedure during same hospitalization in order to minimize chance of further clinical deterioration (examples include, but are not limited to, worsening, sudden chest pain, heart failure, acute myocardial infarction, anatomy, intra-aortic balloon pump, unstable angina with intravenous nitroglycerin or rest angina) (STS/ACC TVT defined "Urgent Status");
3. Every patient that has been informed of the objectives of the study, agreed to participate, has signed the approved consent form, and was willing to accept all relevant examinations and clinical follow-up.

Exclusion Criteria:

1. Anatomically, the approach or aortic root is not suitable for transcatheter aortic valve implantation (TAVI).
2. Anatomical morphology or vascular diseases affecting the device approach.
3. Left ventricular outflow tract obstruction.
4. Primary dilated cardiomyopathy.
5. The echocardiogram indicates the presence of left ventricular thrombus.
6. Cannot tolerate anticoagulation and antiplatelet therapy.
7. Are allergic or resistant to nickel titanium alloys.
8. Active infective endocarditis, or other active infections affecting the effect of TAVI.
9. Severe disabling Alzheimer's disease.
10. Life expectancy\< 6 months.
11. Other conditions (examples include poor compliance of patients and families) considered by the investigator to be inappropriate for participation in this clinical trial.
Relative Bioavailability of Bromhexine Given as Granules and Syrup in Healthy Volunteers (Clinical Phase I Study)

The objective of the current study is to investigate relative bioavailability of bromhexine hydrochloride given as granules and syrup


Eligibility Criteria:
Inclusion criteria:

- Healthy male and female volunteers

Exclusion criteria:

- Any relevant deviation from healthy conditions
Assessment of the Neurosensory Alteration After Inferior Alveolar Nerve Lateralization

: Assessment of the neurosensory alteration with computer guided inferior alveolar nerve lateralization versus non guided classic technique and measuring stability of implant after placement


Eligibility Criteria:
Inclusion Criteria:

* Adult patients with with atrophied posterior mandibular ridge
* both sexes
* NO intra oral soft and hard tissue pathology
* NO systematic that contraindicate implant placement

Exclusion Criteria:

* Presence pathological lesion
* Heavy smokers more than 20 cigarettes per day.
* patients with systemic disease that may affect normal healing
Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma

This trial is a multi-center phase III clinical trial. The purpose of this trial is to explore whether 2 cycles induction chemotherapy combined with concurrent chemoradiotherapy is not inferior to 3 cycles induction chemotherapy combined with concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.


Eligibility Criteria:
Inclusion Criteria:

1. Age 18-65 years old;
2. Pathologically confirmed non-keratinizing nasopharyngeal carcinoma;
3. Stage T3-4N0-1 (according to the UICC/AJCC 8th);
4. No distant metastasis;
5. Have not received anti-cancer treatment in the past;
6. ECOG (Eastern Cooperative Oncology Group of the United States): 0-1;
7. Adequate hematologic, hepatic and renal function.

Exclusion Criteria:

1. The purpose of treatment is palliative;
2. Diagnosed with other malignant tumors at the same time;
3. Malignant tumor history;
4. Pregnancy or breastfeeding, or expect to become pregnant during the clinical trial period;
5. Combined serious illness.
Does Static Ultrasound-Preview Reduce the Incidence of Difficult Lumbar Puncture?

Does the use of ultrasound facilitate a lumbar puncture by reducing the number of difficult and traumatic lumbar punctures?

This is a controlled trial randomizing lumbar puncture patients to groups utilizing ultrasound to preview the bony structures of the spine versus using standard palpation technique. The goal is to determine the helpfulness of ultrasound in performing lumbar punctures (to reduce difficult and traumatic lumbar punctures) among patients whose spines cannot be easily visualized.

Eligibility Criteria:
Inclusion Criteria:

* Age greater than 18
* Clinical need for lumbar puncture
* Unable to visualize spine in position for the lumbar puncture

Exclusion Criteria:

* Able to visualize the spinous processes